Hariharan Subramanian,
Chief Technology Officer
Dr. Subramanian is one of the original developers of PWS Nanocytology, the foundational technology platform behind NanoCytomics. He is currently spearheading the company’s clinical implementation of the technology for risk-stratification applications in colon, lung, prostate, esophageal, ovarian and pancreatic cancers. Dr. Subramanian has considerable experience in the areas of biomedical optics, cancer biology and clinical research, with numerous publications appearing in leading peer-reviewed journals. Dr. Subramanian has received multiple research and business challenge awards, and he serves as a technical reviewer for several scientific and medical journals. He received his PhD in biomedical engineering from Northwestern University.
|
|
|
